论文信息 - Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis. - 字舞流文

Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis.

M. Mingueneau | J. Lyssikatos | T. Bohnert | P. Schroeder | R. Prince | M. Hoemberger | K. Otipoby | J. Santoro | C. Boiselle | Robert S. Meissner | Chungang Gu | B. Hopkins | Bekim Bajrami | D. Burdette | P. Murugan | E. Tien | Isaac E Marx | A. Roach | Douglas Donaldson | Cheryl Black | Sudarshan Kapadnis | Urjana Poreci | Christopher Rowbottom | Kristopher W King | M. Lulla | Tom F. Magee | C. Metrick | Luisette Delva | E. Bame | Bin Ma | Evelyne Polack | Fengmei Zhang | Richard Grater | J. Burns | Josh Johnson | Hao Tang | Doug Burdette | Fengmei Zhang